Showing results (101-110 of 123) with videos related to

Sort By:
Pageof 13
Molecular Oncology|January 7, 2014
Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cellsHua Jiang, Wenhao Zhang, Peipei Shang, et al.
Cancer Medicine|September 4, 2020
Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in ChinaWen Gao, Yuan Jian, Juan Du, et al.
Oncotarget|October 27, 2015
HAG regimen improves survival in adult patients with hypocellular acute myeloid leukemiaXiaoxia Hu, Weijun Fu, Libing Wang, et al.
Hematological Oncology|August 18, 2018
Monoclonal gammopathy of undetermined significance in Chinese population: A prospective epidemiological studyLing Ma, Shuang Xu, Jianhua Qu, et al.
The Journal of Clinical Investigation|October 3, 2018
E-cadherin expression on multiple myeloma cells activates tumor-promoting properties in plasmacytoid DCsEnguang Bi, Rong Li, Laura C Bover, et al.
American Journal of Hematology|April 30, 2022
CAR-T cell therapy targeting B cell maturation antigen is effective for relapsed/refractory multiple myeloma, including cases with poor performance statusJuan Du, Runhong Wei, Songfu Jiang, et al.
The Journal of Urology|June 17, 2024
Radical Prostatectomy Without Prior Biopsy in Selected Patients Evaluated by <sup>18</sup>F-Labeled Prostate-Specific Membrane Antigen-Ligand Positron Emission Tomography/Computed Tomography and Multiparameter Magnetic Resonance Imaging: A Single-Center, Prospective, Single-Arm TrialShaoxi Niu, Xiaohui Ding, Baichuan Liu, et al.
Annals of Hematology|September 3, 2024
Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS StudyWeijun Fu, Soo-Mee Bang, Honghui Huang, et al.
Annals of Hematology|May 23, 2025
Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of the phase 3 OCTANS studyWeijun Fu, Soo-Mee Bang, Honghui Huang, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 19, 2022
Daratumumab, Bortezomib, and Dexamethasone versus Bortezomib and Dexamethasone in Chinese Patients With Relapsed or Refractory Multiple Myeloma: Updated Analysis of LEPUSWeijun Fu, Wei Li, Jianda Hu, et al.
Pageof 13